Design of the SILICOFCM study: Effect of sacubitril/valsartan vs lifestyle intervention on functional capacity in patients with hypertrophic cardiomyopathy

BACKGROUND: Hypertrophic cardiomyopathy (HCM) is the most common genetic cardiovascular disease with a broad spectrum of disease severity. HCM ranges from a benign course to a progressive disorder characterized by angina, heart failure, malignant arrhythmia, syncope, or sudden cardiac death. So far,...

Descripción completa

Detalles Bibliográficos
Autores principales: Tafelmeier, Maria, Baessler, Andrea, Wagner, Stefan, Unsoeld, Bernhard, Preveden, Andrej, Barlocco, Fausto, Tomberli, Alessia, Popovic, Dejana, Brennan, Paul, MacGowan, Guy A., Ristic, Arsen, Velicki, Lazar, Olivotto, Iacopo, Jakovljevic, Djordje G., Maier, Lars S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wiley Periodicals, Inc. 2020
Materias:
Trial Designs
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7244301/
https://www.ncbi.nlm.nih.gov/pubmed/32125709
http://dx.doi.org/10.1002/clc.23346

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7244301/
https://www.ncbi.nlm.nih.gov/pubmed/32125709
http://dx.doi.org/10.1002/clc.23346

Ejemplares similares